Table 1.
Demographics and outcomes of interest of systemic sclerosis patients and controls.
| dcSSc (n = 30) | Controls (n = 30) | p | |
|---|---|---|---|
| Age, mean ± SD years | 58.5 ± 12.4 | 57.6 ± 13.5 | 0.78 |
| Women, no. (%) | 26 (87) | 25 (83) | |
| Raynaud's phenomenon duration, mean ± SD years | 8.8 ± 5 | / | |
| Disease duration (onset of non-RP symptoms), mean ± SD years | 5.6 ± 3.8 | / | |
| IL-33 pg/ml, mean ± SD | 36.8 ± 23.4 | 12.4 ± 8.6 | <0.0001 |
| IL-13 pg/ml, mean ± SD | 0.84 ± 0.65 | 0.35 ± 0.18 | 0.0002 |
| Warrick severity score, mean ± SD | 4.6 ± 4.31 | / | |
| Warrick extension score, mean ± SD | 3.58 ± 3.03 | / | |
| HRCT pulmonary fibrosis, no. (%) | 16 (53) | / | |
| DLCo, mean ± SD | 72 ± 19.9 | / | |
| DLCo <70%, no. (%) | 14 (46) | / | |
| TLC, mean ± SD | 75.8 ± 16.5 | / | |
| TLC <70%, no. (%) | 11 (36) | / | |
| FVC, mean ± SD | 78.5 ± 18.3 | / | |
| FVC <70%„ no. (%) | 11 (36) | / | |
| mRSS, mean ± SD | 18.5 ± 6.2 | / | |
| ANA+, no. (%) | 30 (100) | / | |
| Scl70+, no. (%) | 12 (40) | / | |
| ACA+, no. (%) | 3 (10) | / | |
| RNA III+, no. (%) | 3 (10) | / | |
| SRC, no (%) | 0 (0) | / | |
| Costipation, no (%) | 3 (10) | / | |
| Diarrhea, no (%) | 2 (6) | / | |
| Gastritis, no (%) | 7 (23) | / | |
| Proctitis, no (%) | 2 (6) | / | |
| GERD, no (%) | 19 (63) | / |
The table shows the demographic features and the outcomes of interest of systemic sclerosis patients with diffuse cutaneous form (dcSSc) and healthy controls. No statistical differences were observed in gender or age between the groups while significantly higher concentrations of both IL-33 and IL-13 were found in dcSSc patients. Additionally, autoantibody profile, disease and Raynaud's phenomenon duration, modified Rodnan skin score (mRSS), pulmonary function tests and Warrick scores of scleroderma patients are reported.
dcSSc, diffuse cutaneous form of systemic sclerosis; RP, Raynaud's phenomenon; HRCT, high resolution computed tomography; DLco, diffusion capacity for carbon monoxide; FVC, forced vital capacity; TLC, total lung capacity; ANA, anti-nuclear antibody; Scl70, anti-Scl70 antibody; ACA, anti-centromere antibody; RNA III, anti-RNA polymerase III antibody; SRC, scleroderma renal crisis; GERD, gastroesophageal reflux disease.